hotspot -WSS

hotspot

author：explore 2025-10-01 10:58:27 - browse：12373

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Experimental asthma app from Apple and Anthem shows promise

WSS

Medical school prerequisites are outdated

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Type 2 diabetes prevention programs work at large scale: study

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

focus

hotspot

hotspot

Medicare details structure of new drug price negotiation program

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Medicare proposal to cover medical devices draws a mixed reaction

GOP presidential candidates start declaring their loyalty

At least 13 dead in Texas as scorching temps continue

What health policies could hitch a ride on a spending bill?

Medicare details structure of new drug price negotiation program

Large hospital system sues Multiplan for low

focus

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Novo acquires Inversago for up to $1 billion

NIH chief: government has fallen behind pharma on clinical trials

Ventyx halts psoriasis drug development after lackluster trial results

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Timeline: Special counsel's investigation into Trump's handling of classified documents

leisure time

focus

knowledge

focus